NCT03483883 is a Phase 1 clinical trial of Avelumab in Metastatic sRCC, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT03483883?

NCT03483883 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT03483883?

Interventions in NCT03483883: Avelumab, Gemcitabine.

What condition does NCT03483883 study?

NCT03483883 studies Metastatic sRCC.

Is NCT03483883 still recruiting?

NCT03483883 is currently terminated. Last updated 26 August 2022.

Last reviewed 2022-08-26 · How we verify

NCT03483883

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avelumab/Gemcitabine in Sarcomatoid RCC

Terminated Phase 1 Last updated 26 August 2022

What this trial tests

Phase 1 trial testing Avelumab in Metastatic sRCC in 6 participants. Terminated before completion.

Timeline

19 March 2018

Primary endpoint
22 July 2020

10 February 2021

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	19 March 2018
Primary completion	22 July 2020
Estimated completion	10 February 2021
Sites	1 location across United States

Drugs / interventions tested

Avelumab (avelumab) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Metastatic sRCC — all drugs for Metastatic sRCC →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Metastatic sRCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Product review: avelumab, an anti-PD-L1 antibody.
Collins JM, Gulley JL. · · 2019 · cited 62× · PMID 30481100 · DOI 10.1080/21645515.2018.1551671
PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.
Ding L, Dong HY, Zhou TR, Wang YH, et al · · 2021 · cited 15× · PMID 34382349 · DOI 10.1002/cam4.4190

Verify or expand the search:

Other trials of Avelumab

Trials testing the same drug.

NCT06939036 — Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) · Phase 1, PHASE2 · terminated
NCT05687721 — Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer · Phase 1, PHASE2 · withdrawn
NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
NCT06424717 — Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L · Phase 2 · withdrawn
NCT06302426 — Trial of INI-4001 in Patients With Advanced Solid Tumours · Phase 1 · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03483883 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 26 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03483883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing